1. Home
  2. BEAM vs ADUS Comparison

BEAM vs ADUS Comparison

Compare BEAM & ADUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$24.47

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Logo Addus HomeCare Corporation

ADUS

Addus HomeCare Corporation

HOLD

Current Price

$92.82

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
ADUS
Founded
2017
1979
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Nursing Services
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
1.8B
IPO Year
2019
2009

Fundamental Metrics

Financial Performance
Metric
BEAM
ADUS
Price
$24.47
$92.82
Analyst Decision
Strong Buy
Buy
Analyst Count
14
10
Target Price
$52.21
$135.40
AVG Volume (30 Days)
1.8M
185.0K
Earning Date
05-05-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
82.31
23.40
EPS
N/A
5.22
Revenue
$24,000.00
N/A
Revenue This Year
N/A
$9.17
Revenue Next Year
$32.20
$4.64
P/E Ratio
N/A
$17.82
Revenue Growth
33.33
N/A
52 Week Low
$13.98
$91.10
52 Week High
$36.44
$124.44

Technical Indicators

Market Signals
Indicator
BEAM
ADUS
Relative Strength Index (RSI) 46.78 32.17
Support Level $23.42 N/A
Resistance Level $25.69 $118.51
Average True Range (ATR) 1.37 2.97
MACD 0.16 -0.37
Stochastic Oscillator 65.75 15.19

Price Performance

Historical Comparison
BEAM
ADUS

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About ADUS Addus HomeCare Corporation

Addus HomeCare Corp is engaged in the provision of in-home care services. The Company has three reportable segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living, mainly to the elderly, chronically ill, and disabled individuals. The Hospice segment provides physical, emotional, and spiritual care for terminally ill patients and their families. The Home Health segment provides medical services to individuals requiring care during illness or recovery. It generates the majority of its revenue from the Personal Care segment.

Share on Social Networks: